

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : WALTER SCHUBERT
Application No. :
Filed : Herewith
For : UTILIZATION OF AN AMINOPEPTIDASE
INHIBITOR
Examiner :
Attorney's Docket : HSS-022XX

Group Art Unit:

I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in an
envelope addressed to: Commissioner for Patents, Washington,
D.C. 20231 on _____.

By: _____
Charles L. Gagnebin III
Registration No. 25,467
Attorney for Applicant

PRELIMINARY AMENDMENT

BOX PCT
Commissioner for Patents
Washington, D.C. 20231

Sir:

Kindly enter the following Preliminary Amendment in the
above-identified application:

In the Claims:

WEINGARTEN, SCHURGIN,
GAGNEBIN & HAYES, LLP
TEL. (617) 542-2290
FAX. (617) 451-0313

Express Mail Number
EL 634465013 US

Please amend the Claims to read as follows (a copy of the amended claims showing the additions and deletions appears at the end for the Examiner's convenience):

4. The utilization as claimed in claim 1

characterized in that

for producing said medicament, at least one additional inhibitor is used which inhibits at least one surface protein that is not an aminopeptidase.

8. A pharmaceutical preparation which can be produced using at least one aminopeptidase inhibitor or a combination of at least one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claim 1.

11. The method as claimed in claim 9

characterized in that

said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one aminopeptidase inhibitor identified in step d) to the organ-

specific endothelial cells and/or to the organ-specific extracellular structures is detected, and in which the detected bindings are compared.

14. The method as claimed in claim 12

characterized in that

said method includes a further step, following step d), in which the at least one aminopeptidase inhibitor identified in step d) or a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor is added to at least one polarizing tumor cell and/or immune cell, and the further development of the at least one polarizing tumor cell and/or immune cell is detected.

15. The method as claimed in claim 12

characterized in that

said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one inhibitor identified in step d) or with a combination of the at least one inhibitor identified in step d) and at least one

aminopeptidase inhibitor to the organ-specific endothelial cells and/or to the organ-specific extracellular structures is detected, and in which the detected bindings are compared.

Please add the following new claims 16-26:

16. The utilization as claimed in claim 2
characterized in that
for producing said medicament, at least one additional inhibitor is used which inhibits at least one surface protein that is not an aminopeptidase.

17. The method as claimed in claim 10
characterized in that
said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one aminopeptidase inhibitor identified in step d) to the organ-specific endothelial cells and/or to the organ-specific

extracellular structures is detected, and in which the detected bindings are compared.

18. The method as claimed in claim 13

characterized in that

said method includes a further step, following step d), in which the at least one aminopeptidase inhibitor identified in step d) or a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor is added to at least one polarizing tumor cell and/or immune cell, and the further development of the at least one polarizing tumor cell and/or immune cell is detected.

19. The method as claimed in claim 13

characterized in that

said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one inhibitor identified in step d) or with a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor to the organ-specific endothelial cells

09537151-010303

and/or to the organ-specific extracellular structures is detected, and in which the detected bindings are compared.

20. The method as claimed in claim 14

characterized in that

said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one inhibitor identified in step d) or with a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor to the organ-specific endothelial cells and/or to the organ-specific extracellular structures is detected, and in which the detected bindings are compared.

21. A pharmaceutical preparation which can be produced using at least one aminopeptidase inhibitor or a combination of at least one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claim 2.

22. A pharmaceutical preparation which can be produced using at least one aminopeptidase inhibitor or a combination of at least

one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claim 3.

23. A pharmaceutical preparation which can be produced using at least one aminopeptidase inhibitor or a combination of at least one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claim 4.

24. A pharmaceutical preparation which can be produced using at least one aminopeptidase inhibitor or a combination of at least one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claim 5.

25. A pharmaceutical preparation which can be produced using at least one aminopeptidase inhibitor or a combination of at least one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claim 6.

26. A pharmaceutical preparation which can be produced using at least one aminopeptidase inhibitor or a combination of at least one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claim 7.

Attorney Docket No. HSS-022XX
Filed: Herewith
Group Art Unit:


REMARKS

This Preliminary Amendment puts the claims into proper form for examination. Note that claims 4, 8, 11, 14, and 15 have been amended; new claims 16-26 have been added; and claims 1-3, 5-7, 9, 10, 12, and 13 remain unchanged. Kindly calculate the filing fee based on the amended claims.

The Examiner is encouraged to telephone the undersigned attorney to discuss any matter which would expedite allowance of the present application.

Respectfully submitted,

WALTER SCHUBERT

By: 
Charles L. Gagnebin III
Registration No. 25,467
Attorney for Applicant

WEINGARTEN, SCHURGIN, GAGNEBIN
& HAYES LLP
Ten Post Office Square
Boston, MA 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

Date: 9-21-1

CLG/mc/258949-1
Enclosure

04537191 010302

Red-lined Claims for the Examiner's convenience:

4. The utilization as claimed in claim 1-~~or~~-2

characterized in that

for producing said medicament, at least one additional inhibitor is used which inhibits at least one surface protein that is not an aminopeptidase.

8. A pharmaceutical preparation which can be produced using at least one aminopeptidase inhibitor or a combination of at least one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claims 1-~~to~~-7.

11. The method as claimed in ~~one of~~ claims 9-~~or~~-10

characterized in that

said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one aminopeptidase inhibitor identified in step d) to the organ-specific endothelial cells and/or to the organ-specific

extracellular structures is detected, and in which the detected bindings are compared.

14. The method as claimed in ~~one of claims 12 or 13~~
characterized in that

said method includes a further step, following step d), in which the at least one aminopeptidase inhibitor identified in step d) or a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor is added to at least one polarizing tumor cell and/or immune cell, and the further development of the at least one polarizing tumor cell and/or immune cell is detected.

15. The method as claimed in ~~one of claims 12 to 14~~
characterized in that

said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one inhibitor identified in step d) or with a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor to the organ-specific endothelial cells

Attorney Docket No. HSS-022XX
Filed: Herewith
Group Art Unit:

and/or to the organ-specific extracellular structures is
detected, and in which the detected bindings are compared.

0937191-010302

-11-

WEINGARTEN, SCHURGIN,
GAGNEBIN & HAYES, LLP
TEL. (617) 542-2290
FAX. (617) 451-0313